Zurich Corporate Risk introduces Precision CancerCare

Zurich Corporate Risk has introduced its new Precision CancerCare service for both new and reviewing customers.

Provided in partnership with Further, a specialist in niche health service solutions, the service offers access to comprehensive genetic testing using the latest tumour profiling technology and expert medical panels.

Cancer is the leading cause of claim for Zurich Corporate Risk, and ensuring customers and their employees have the best support is a primary focus.

Precision CancerCare is available for all advanced and complex cancers, providing customised treatment plans based on the molecular drivers of the tumour.

This approach aims to improve patient outcomes, reduce negative side effects of unnecessary treatments, and enhance overall quality of life.

The service also delivers a clinical report with personalised guidance on treatment options and advice.

Key features include testing in world-leading laboratories, expert-reviewed results, navigation assistance on clinical trials, and coordination with the employee’s treating clinician.

If a hereditary mutation is identified, children are offered testing and counselling.